Harrow Health Inc. 11.875... (HROWM)
NASDAQ: HROWM
· Real-Time Price · USD
26.03
0.03 (0.12%)
At close: Sep 26, 2025, 3:58 PM
25.99
-0.15%
After-hours: Sep 26, 2025, 04:00 PM EDT
Company Description
Harrow, Inc. engages in the development, production, and sale of innovative medications.
It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.
The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business.
The company was founded by Mark L.
Baum and Robert J.
Kammer in January 2006 and is headquartered in Nashville, TN.
Harrow Health Inc. 11.875% Senior Notes due 2027
| Country | United States |
| IPO Date | Dec 29, 2022 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 217 |
| CEO | Mark L. Baum |
Contact Details
Address: No Address available Nashville, United States | |
| Website | http://www.harrowinc.com |
Stock Details
| Ticker Symbol | HROWM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001360214 |
| CUSIP Number | n/a |
| ISIN Number | US4158583074 |
| Employer ID | 45-0567010 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 19, 2025 | 8-K | Current Report |
| Sep 12, 2025 | 8-K | Current Report |
| Sep 09, 2025 | 4 | Filing |
| Sep 09, 2025 | 3 | Filing |
| Sep 09, 2025 | 8-K | Current Report |
| Sep 08, 2025 | 8-K | Current Report |
| Aug 25, 2025 | 8-K | Current Report |
| Aug 11, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |
| Jul 23, 2025 | 4 | Filing |